GLP-3 RT (10mg)
Spécifications techniques
| Pureté (HPLC) | ≥97% (HPLC) |
| Numéro CAS | 2381089-83-2 |
| Forme | White lyophilized powder |
| Stockage | -20°C |
| Séquence | Modified triple incretin agonist |
| Poids moléculaire | 4,803.56 g/mol |
| Forme saline | Acetate |
| Solubilité | Soluble in aqueous buffer |
GLP-3 RT (10mg)
Prix catalogue EUR · HU, SK, CZ, PL
- Eurozone (EUR)252,00 EUR
- Hongrie (HU)252,00 EUR≈ 100 800 Ft
- Slovaquie (SK)252,00 EUR
- Tchéquie (CZ)252,00 EUR≈ 6 300 Kč
- Pologne (PL)252,00 EUR≈ 1071,00 zł
Même prix catalogue en EUR pour livraison vers la Hongrie, la Slovaquie, la République tchèque et la Pologne. Paiement en EUR.
Montants HUF/CZK/PLN indicatifs convertis depuis l’EUR ; la Slovaquie utilise l’EUR. Taux approximatifs. Paiement en EUR.
Triple agonist (GLP-1/GIP/Glucagon) for metabolic research.
Mechanism: GLP-1 (appetite), GIP (insulin sensitivity), Glucagon (thermogenesis).
Applications: Obesity, NAFLD/NASH, metabolic syndrome.
Protocol: Reconstitute 2ml BAC water. Store -20°C. Do not vortex.
Strictement réservé à la recherche en laboratoire.
Non destiné à la consommation humaine, vétérinaire ou au diagnostic.
From the Peptide Explorer
The first triple-incretin receptor agonist targeting GIP, GLP-1, and glucagon receptors simultaneously. Phase 2 data demonstrated the largest weight reductions reported for any anti-obesity molecule, positioning it as a next-generation metabolic research compound.
Key Mechanisms
- ›GIP receptor agonism
- ›GLP-1 receptor agonism
- ›Glucagon receptor agonism (energy expenditure)
- ›Hepatic lipid metabolism enhancement
- ›Appetite suppression via CNS pathways
Primary Research Areas
- ›Obesity
- ›NASH
- ›Metabolic syndrome
- ›Triple-incretin signaling
- ›Energy expenditure
Key Research Findings
- Phase 2: up to 24.2% body weight reduction at 48 weeks (highest reported for any molecule)
- Glucagon component uniquely increases energy expenditure
- Significant reduction in liver fat content in NAFLD models
Research Overview
The first triple-incretin receptor agonist targeting GIP, GLP-1, and glucagon receptors simultaneously. Phase 2 data demonstrated the largest weight reductions reported for any anti-obesity molecule, positioning it as a next-generation metabolic research compound.
Origin: Triple GIP/GLP-1/glucagon receptor agonist by Eli Lilly
Mechanism of Action
- GIP receptor agonism
- GLP-1 receptor agonism
- Glucagon receptor agonism (energy expenditure)
- Hepatic lipid metabolism enhancement
- Appetite suppression via CNS pathways
Primary Research Areas
- Obesity
- NASH
- Metabolic syndrome
- Triple-incretin signaling
- Energy expenditure
Key Published Findings
- Phase 2: up to 24.2% body weight reduction at 48 weeks (highest reported for any molecule)
- Glucagon component uniquely increases energy expenditure
- Significant reduction in liver fat content in NAFLD models
Research Protocol
Commonly studied routes: Subcutaneous. Reconstitute with bacteriostatic water. Consult published literature for dose ranges; use our Peptide Calculator for volumetric preparation.
Storage
2-8°C
Important Notice
Retatrutide (10mg) is supplied for laboratory research use only (RUO). Not for human or veterinary use, diagnostics, or therapeutics.
Spécifications de recherche
Synthesized for strict analytical consistency. Verified via HPLC/MS.Voir les standards qualité →
Manipulation et stockage
- Store lyophilized at -20°C
- Protect from light and moisture
- Use sterile bacteriostatic water for reconstitution
- Minimize freeze-thaw cycles
- Solubility: Soluble in aqueous buffer
Questions fréquentes
What is GLP-3 RT (10mg)?▼
Is GLP-3 RT (10mg) intended for human consumption?▼
How do you verify purity and identity?▼
How should GLP-3 RT (10mg) be stored?▼
Do you provide a Certificate of Analysis (COA)?▼
What purity is GLP-3 RT (10mg)?▼
Verified Research Reviews
Reta is amazing
"really amazing compound and interesting "